Laddar...
Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib
Ruxolitinib was an effective salvage therapy for relapsed/refractory secondary hemophagocytic lymphohistiocytosis. Prolonged maintenance with a ruxolitinib taper obviated the need for intensive chemotherapy or allogeneic transplant in secondary HLH.
Sparad:
| I publikationen: | Blood Adv |
|---|---|
| Huvudupphovsmän: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
American Society of Hematology
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6963250/ https://ncbi.nlm.nih.gov/pubmed/31821455 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000898 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|